ReviewFrontiers in bioengineering and biotechnology2026
From passive sealing to active microenvironment remodeling: design strategies, biological effects, and translational challenges of multifunctional hydrogels for postoperative pancreatic fistula prevention.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative pancreatic fistula (POPF) remains one of the most common and potentially lethal complications following pancreatic surgery, with reported incidence rates ranging from 20% to 64%. Conventional sealing materials-including fibrin glue and polyglycolic acid felt-face rapid degradation in the protease-rich pancreatic microenvironment and loss of adhesion in wet conditions, resulting in a marked contradiction between early positive randomized trials and subsequent negative meta-analyses. In recent years, multifunctional hydrogels have been driving a conceptual transition from "passive physical barriers" to "active microenvironment remodeling" for POPF prevention. This review examines hydrogel design strategies tailored to the extreme postoperative pancreatic microenvironment across multiple dimensions: in the domain of enzyme management, we compare the active enzyme-capturing strategy based on D-amino acid peptides, the enzyme-cleavage-site-elimination strategy using recombinant collagen, and the structural tolerance strategy of self-assembling peptides; in structural-functional integration, we analyze how asymmetric bilayer designs simultaneously achieve wet tissue sealing and anti-adhesion; in functional integration, we delineate the evolutionary trajectory of PVA-based platforms from pure physical barriers to antibacterial/anti-inflammatory/pro-healing multifunctional composites; and in the temporal dimension, we evaluate innovative therapeutic frameworks including "full-cycle management" and dual-functional integration of POPF prevention with tumor immunotherapy. We further provide a critical analysis of key translational gaps from five perspectives: species disparities in animal models, quantitative matching of degradation kinetics with anastomotic healing windows, surgical handlability, scalable manufacturing and sterilization, and the diagnostic-therapeutic closed loop. Among the studies reviewed, all therapeutic multifunctional hydrogels remain at the proof-of-concept stage, predominantly in rat models, with SmartPAN-a diagnostic leak indicator-being the only POPF-related hydrogel device to have entered human trials. Establishing standardized pancreatic juice tolerance assessment systems, validating long-term efficacy and safety in large animal models, and achieving precise quantitative matching between degradation kinetics and anastomotic healing timelines represent the most urgent tasks for advancing clinical translation in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.